Related Experiment Video
Updated: Feb 2, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to
1a Department of Biochemistry and Immunology , Vejle Hospital , Vejle , Denmark.
Abstract:
Introduction: Analysis of circulating tumor DNA is a promising approach to guide the treatment of cancer patients but despite large efforts it has not been broadly applied in the clinic. Technical obstacles and lack of standardization have hampered the process and it has proved challenging to make highly sensitive analyses available for all patients. Research has focused on the use of somatic mutations but because of large mutational diversity among patients the setup becomes unmanageable for daily routine use. Areas covered: Methylations are key events in cancer development and can be used as markers for the presence of circulating tumor DNA similar to how mutations have been used. This review focuses on analytical aspects and possible clinical applications of methylated ctDNA in plasma from cancer patients. Expert commentary: Technical and clinical challenges of mutation and methylation analyses are similar. However, the possibility to analyze a limited number of methylations present in all tumors of a certain type allows for proper validation and standardization of the analyses. Tumor-specific methylation analyses could supplement or substitute mutation analyses for certain clinical applications and assist the progress of the clinical use of circulating tumor DNA.
Insights
Methylated circulating tumor DNA (ctDNA) shows promise for cancer treatment guidance. Analyzing specific tumor methylations offers a standardized, manageable approach compared to mutation analysis for broader clinical application.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biomarker Discovery
Background:
- Circulating tumor DNA (ctDNA) analysis is a promising tool for cancer patient treatment guidance.
- Clinical application of ctDNA analysis is hindered by technical challenges and lack of standardization.
- Current focus on somatic mutations faces challenges due to high patient-specific mutational diversity.
Purpose of the Study:
- To review the analytical aspects and clinical applications of methylated ctDNA in patient plasma.
- To explore methylation analysis as a viable alternative to mutation analysis for ctDNA detection.
Main Methods:
- Review of current literature on methylated ctDNA analysis.
- Focus on analytical methodologies and clinical utility.
- Comparison of methylation-based markers with mutation-based markers.
Main Results:
- Methylations are crucial in cancer development and serve as effective ctDNA markers.
- Analysis of a limited set of tumor-specific methylations allows for standardization and validation.
- Methylation analysis presents similar technical and clinical challenges to mutation analysis.
Conclusions:
- Tumor-specific methylation analyses can supplement or replace mutation analyses in certain clinical scenarios.
- Standardized methylation analysis of ctDNA can facilitate broader clinical adoption.
- Methylated ctDNA analysis holds significant potential to advance the clinical use of ctDNA.
Related Concept Videos
Mutations
Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
Clinical Applications of Epidermal Stem Cells
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Cell Specific Gene Expression

